Literature DB >> 16333099

Distribution of Streptococcus pneumoniae serotypes responsible for penicillin resistance and the potential role of new conjugate vaccines in New Caledonia.

N Michel1, M Watson, F Baumann, P Perolat, B Garin.   

Abstract

Invasive pneumococcal disease is a significant cause of morbidity and mortality worldwide. The aim of this study was to establish the serotypes responsible for pneumococcal disease and the serotypes responsible for penicillin resistance in Noumea, New Caledonia. Isolates of Streptococcus pneumoniae from all body sites referred to the Microbiology Department of the Pasteur Institute in New Caledonia between May 1999 and May 2001 had serotyping and susceptibility testing performed. Basic demographic data on patients were also collected. A total of 298 isolates were included in the study. The most common serotypes were types 1 (20%), 23F (10%), 12F (8%), 19F (8%), and 6B (5%). The serotype distribution differed significantly with age, site of collection, and ethnicity. Overall, 280 of 298 (94%) of the isolates had serogroups that are included in the 23-valent vaccine. However, only 14 of 20 (70%) of the isolates associated with invasive disease from children younger than 5 years of age and 26 of 113 (23%) of invasive isolates from patients more than 5 years of age were included in the new 7-valent conjugate vaccine. Overall, reduced susceptibility to penicillin was found in 43 of 298 (14.4%) of the isolates, with 13% falling into the intermediate resistance category and only 5 (2%) being high-level resistant. A higher prevalence of penicillin resistance occurred in younger age groups and in European patients and involved specifically certain serotypes. The 7-valent conjugate pneumococcal vaccine has potential benefit for the New Caledonian population under 5 years of age and should be considered for future vaccines schedules.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16333099      PMCID: PMC1317162          DOI: 10.1128/JCM.43.12.6060-6063.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Pneumococcal infections in Victoria, Australia.

Authors:  G Hogg; J Strachan
Journal:  Vaccine       Date:  1999-07-30       Impact factor: 3.641

2.  Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates.

Authors:  Angela B Brueggemann; Brian G Spratt
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

3.  Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics.

Authors:  L P Jetté; F Lamothe
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

4.  Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine.

Authors:  S B Black; H R Shinefield; J Hansen; L Elvin; D Laufer; F Malinoski
Journal:  Pediatr Infect Dis J       Date:  2001-12       Impact factor: 2.129

5.  Are current recommendations for pneumococcal vaccination appropriate for Western Australia? The Vaccine Impact Surveillance Network--Invasive Pneumococcal Study Group.

Authors: 
Journal:  Med J Aust       Date:  2000-10-02       Impact factor: 7.738

6.  Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines.

Authors:  R Dagan; N Givon-Lavi; L Shkolnik; P Yagupsky; D Fraser
Journal:  J Infect Dis       Date:  2000-04-07       Impact factor: 5.226

7.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

8.  Multinational study of pneumococcal serotypes causing acute otitis media in children.

Authors:  William P Hausdorff; Greg Yothers; Ron Dagan; Terhi Kilpi; Stephen I Pelton; Robert Cohen; Michael R Jacobs; Sheldon L Kaplan; Corinne Levy; Eduardo L Lopez; Edward O Mason; Vassiliki Syriopoulou; Brian Wynne; John Bryant
Journal:  Pediatr Infect Dis J       Date:  2002-11       Impact factor: 2.129

9.  Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California.

Authors:  Steven Black; Henry Shinefield
Journal:  Eur J Pediatr       Date:  2002-11-09       Impact factor: 3.183

Review 10.  Pneumococcal vaccine trials in Papua New Guinea: relationships between epidemiology of pneumococcal infection and efficacy of vaccine.

Authors:  I D Riley; D Lehmann; M P Alpers
Journal:  Rev Infect Dis       Date:  1991 May-Jun
View more
  3 in total

1.  Invasive serotype 1 Streptococcus pneumoniae outbreaks in the South Pacific from 2000 to 2007.

Authors:  S Le Hello; M Watson; M Levy; S Marcon; M Brown; J F Yvon; I Missotte; B Garin
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

2.  Population structure of hyperinvasive serotype 12F, clonal complex 218 Streptococcus pneumoniae revealed by multilocus boxB sequence typing.

Authors:  Alexey V Rakov; Kimiko Ubukata; D Ashley Robinson
Journal:  Infect Genet Evol       Date:  2011-08-25       Impact factor: 3.342

3.  Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice.

Authors:  Kaifeng Wu; Xuemei Zhang; Jing Shi; Nan Li; Dairong Li; Miao Luo; Ju Cao; Nanlin Yin; Hong Wang; Wenchun Xu; Yujuan He; Yibing Yin
Journal:  Infect Immun       Date:  2009-12-28       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.